Growth factors and antiapoptotic signaling pathways in multiple myeloma (Q36292888)

13 August 2017

1 reference

title

Growth factors and antiapoptotic signaling pathways in multiple myeloma (English)

1 reference

13 August 2017

author

Niels W C J van de Donk

series ordinal

1

object named as

van de Donk NW

1 reference

13 August 2017

2

Lokhorst HM

1 reference

13 August 2017

3

Bloem AC

1 reference

13 August 2017

publication date

1 December 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

19

1 reference

13 August 2017

issue

12

1 reference

13 August 2017

page(s)

2177-2185

1 reference

Apoptosis: a link between cancer genetics and chemotherapy

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor α

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Illegitimate WNT signaling promotes proliferation of multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Downstream effectors of oncogenic ras in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Ras oncogene mutation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

NF-kappa B as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

The AKT kinase is activated in multiple myeloma tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Apoptotic cell death induced by c-myc is inhibited by bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Identification of genes modulated in multiple myeloma using genetically identical twin samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

IL-6-independent expression of Mcl-1 in human multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Radiation-induced apoptosis in human myeloma cell line increases BCL-2/BAX dimer formation and does not result in BAX/BAX homodimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Regulation of the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

Secretion of insulinlike growth factor I and insulinlike growth factor-binding proteins by murine bone marrow stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

7 January 2021

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

7 January 2021

BCL-2 family members and the mitochondria in apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

7 January 2021

Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl‐2 oncoprotein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

7 January 2021

Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

7 January 2021

Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6(IL-6)-induced growth and survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

7 January 2021

Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403970

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403970

1 reference

release_egidckkulrfevbygk2mnwdu7vi

13 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/egidckkulrfevbygk2mnwdu7vi

24 November 2022

mapped directly with Wikidata item

1 reference